Skip to main content

The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research Workshop Summary (2015) / Chapter Skim
Currently Skimming:

Appendix B: Workshop Agenda
Pages 59-62

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 59...
... Appendix B Workshop Agenda June 8, 2015 7:30 am Registration 8:00 am Welcome from the National Cancer Policy Forum Sharyl Nass, Institute of Medicine Director, National Cancer Policy Forum Overview of the Workshop Michael Kastan, Duke Cancer Institute Planning Committee Chair 8:15 am Session 1: Overview and Value of Trials That Include Pets in Translational Cancer Research Moderator: Michael Kastan, Duke Cancer Institute Overview of current challenges and opportunities in oncology drug development Lee Helman, National Cancer Institute Strengths and limitations of traditional preclinical models Beverly Teicher, National Cancer Institute 59
Read the entire page →
From page 60...
... 60 CLINICAL STUDIES FOR PETS WITH CANCER Advantages and experiences with trials that include animal patients Chand Khanna, National Cancer Institute Group Discussion 10:10 am Break 10:20 am Session 2: Canine Tumor Biology and Genomics Informing Cancer Drug Development Moderator: Deborah Knapp, Purdue University  current state of canine tumor genetics and scientific The limitations Heidi Parker, National Human Genome Research Institute  and availability of canine cancer tissue banks in Use ­translational research Matthew Breen, North Carolina State University Genomic resources for canine cancer research Jessica Alföldi, Broad Institute of the Massachusetts Institute of Technology and Harvard University Biology and informatics needs Jeff Trent, Translational Genomics Research Institute Group Discussion 12:15 pm Lunch Break 1:00 pm Session 3: Effectively Integrating Biomarkers into Study Designs Moderator: Carl Barrett, AstraZeneca Opportunities for preclinical evaluation of novel therapies Timothy Fan, University of Illinois at Urbana-Champaign
Read the entire page →
From page 61...
... and potential predictive biomarkers Doug Thamm, Colorado State University Group Discussion 2:30 pm Session 4: Effectively Integrating Imaging Technologies into Study Designs Moderator: Peter Choyke, National Cancer Institute Role of trials that include pets in the development of new imaging modalities Peter Choyke, National Cancer Institute Role of magnetic resonance imaging in studying tumor physiology: A clinical perspective Mark Dewhirst, Duke University Group Discussion 3:30 pm Break 3:45 pm Session 5: Mechanisms for Comparative Oncology Trials Moderator: Lou DeGennaro, Leukemia & Lymphoma Society Single-institution studies Cheryl London, Ohio State University Multi-institution studies Amy LeBlanc, National Cancer Institute Group Discussion 4:45 pm Wrap Up Day 1
Read the entire page →
From page 62...
... 62 CLINICAL STUDIES FOR PETS WITH CANCER June 9, 2015 7:30 am Registration 8:00 am  6: Addressing the Needs of Pet Animals and Session Their Owners Moderator: Michael Lairmore, University of California, Davis Trial design and appropriate oversight David Vail, University of Wisconsin–Madison Best practices for conduct of clinical trials for animal patients Rod Page, Colorado State University Patricia Olson, Independent Advisor on Animal Health and Welfare Group Discussion 9:45 am Break 10:00 am Session 7: The Status of Comparative Oncology in Drug Development Moderator: Perry Nisen, Sanford-Burnham Medical Discovery Institute Panelists: Anne Keane, Achaogen John Leighton, Food and Drug Administration Wendy Levin, Fate Therapeutics Daniel Tumas, Gilead Sciences, Inc. Group Discussion 11:30 am Workshop Wrap Up Deborah Knapp, Purdue University Len Lichtenfeld, American Cancer Society 12:00 pm Adjourn
Read the entire page →

Key Terms

  • colorado state
  • peter choyke
  • effectively integrating
  • imaging technologies
  • doug thamm

  • resonance imaging
  • cheryl london
  • integrating imaging
  • oncology trials
  • amy leblanc

  • studying tumor
  • comparative oncology
  • national cancer
  • state university
  • include pets

  • study designs
  • clinical perspective
  • magnetic resonance
  • imaging modalities
  • potential predictive

  • predictive biomarkers
  • ohio state
  • duke university
  • lou degennaro
  • mark dewhirst

  • lymphoma society


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.